Growth Hormone Axis Research Peptides: What the Human Data Actually Shows

The short version

Growth hormone is made in the pituitary, a gland about the size of a pea sitting under the brain. It comes out in bursts - pulses - mostly overnight, and the liver answers those pulses by making IGF-1, a growth signal that circulates in the blood. The three compounds catalogued here all push on that system rather than replacing it: they prompt the pituitary to release its own growth hormone instead of supplying growth hormone from a vial.

That is where the similarity ends. One of them, tesamorelin (Egrifta), is an approved prescription medicine with 52-week randomized data behind it. One, ipamorelin, has a single published Phase 2 trial that missed its main goal. The third is not a compound at all but a pairing of two peptides that has never been tested together in a controlled study.

This desk reports what was measured, in whom, by what method and for how long. It sells nothing, recommends no dose, and treats a mechanism and an outcome as two different kinds of claim.

What a research peptide is, and what the phrase is doing

A peptide is a short chain of amino acids - the same building blocks proteins are made of, just fewer of them. The compounds here are synthetic peptides designed to bind a specific receptor on pituitary cells and provoke a growth-hormone pulse. A secretagogue, in this context, is simply something that makes a gland secrete.

The phrase research peptide is doing real work in that description, and it is worth being precise about it. Ipamorelin and the CJC-1295 pairing hold no approved human indication anywhere and are sold as research chemicals; in 2024 the FDA removed ipamorelin acetate from Category 2 of the interim Section 503A bulk drug substances list after the nominator withdrew, and reviewed the substance at the October 2024 Pharmacy Compounding Advisory Committee meeting. Tesamorelin is the exception. It was approved in the United States in 2010 to reduce excess abdominal fat in HIV-infected patients with antiretroviral-related lipodystrophy ^[13], and every other application discussed for it is off-label.

All three are prohibited in sport at all times under the WADA Prohibited List category S2, and accredited laboratories have established detection methods for the class. None of that is a reason to ignore the literature. It is a reason to read it carefully and to keep the regulatory line visible on every page rather than tucked into a footer.

From bench findings to study design

This desk reads the growth-hormone axis from the applied end. The mechanistic case for a secretagogue is easy to state and has been settled for decades: bind the GHRH receptor or the ghrelin receptor on a pituitary somatotroph, raise cyclic AMP or intracellular calcium, and growth hormone comes out. What is harder - and what actually separates these three compounds from one another - is what happened when someone designed a study around that mechanism and committed to an endpoint in advance.

Design choices decide what a result is allowed to mean. Ipamorelin's only Phase 2 trial enrolled 114 adults undergoing bowel resection, gave 0.03 mg/kg intravenously twice daily for up to seven days, and measured time to first tolerated meal; the median was 25.3 hours against 32.6 hours on placebo, which did not reach significance at p=0.15 ^[3]. The human pharmacokinetic dataset underpinning everything else said about ipamorelin comes from eight volunteers per dose level receiving five fifteen-minute intravenous infusions ^[4]. Tesamorelin's visceral-fat effect, by contrast, was measured by computed tomography and by proton magnetic resonance spectroscopy in placebo-controlled trials running 26 and 52 weeks ^[14][16].

Route, duration, population, endpoint and measurement modality: those five choices are why one of these compounds carries a label and two do not.

Three evidence bases at three different maturities

Read as a set, the members occupy three distinct positions on the evidence ladder, and that ladder is the most useful thing this hub has to offer.

Tesamorelin sits at the top. Five randomized controlled trials have been pooled in a 2026 meta-analysis reporting a mean difference of -27.71 cm2 in visceral adipose tissue, -4.28% in hepatic fat fraction and +1.42 kg in lean body mass, with no serious adverse events and no glucose perturbation ^[8]. That is a replicated, imaging-confirmed effect in a defined population.

Ipamorelin sits near the bottom of the human ladder and near the top of the preclinical one. Its founding characterization established it as the first highly GH-selective secretagogue, releasing growth hormone in primary rat pituitary cells, in anesthetized rats and in conscious swine - with a swine ED50 of 2.3 nmol/kg against 3.9 nmol/kg for GHRP-6 - without raising ACTH or cortisol above the level seen with GHRH, even at doses more than 200-fold above its GH ED50 ^[6]. That is an elegant pharmacology result. It is not an outcome.

The CJC-1295 plus ipamorelin pairing sits off the ladder entirely. Each half has its own literature: a single subcutaneous dose of CJC-1295 with DAC raised mean plasma growth hormone two- to ten-fold for six days or more and IGF-1 1.5- to three-fold for nine to eleven days in healthy adults ^[10]. The combination itself has never been the subject of a controlled human trial. A 2026 narrative review reached the same conclusion, finding that CJC-1295 with ipamorelin improved maximum tetanic tension in a murine glucocorticoid-induced muscle-loss model while noting that the evidence remains limited to animal studies and that safety and dosing data remain unknown ^[7].